Skip to content

Predicting the pathological response to neoadjuvant chemotherapy based on metabolomics in locally advanced gastric cancer

Predicting the pathological response to neoadjuvant chemotherapy based on metabolomics in locally advanced gastric cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300074543
Enrollment
Unknown
Registered
2023-08-09
Start date
2023-08-04
Completion date
Unknown
Last updated
2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer

Interventions

health control:none
NCT-sensitive:Neoadjuvant chemotherapy
NCT-resistant:Neoadjuvant chemotherapy

Sponsors

The First Affiliated Hospital of Xiamen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Health controls should undergo gastroscopy and do not have history of hyperthyroidism,diabetes or other metabolic disease 2.Diagnosed with gastric carcinoma by biopsy 3.hyperthyroidism,diabetes or other metabolic disease should be excluded 4.Undergo radical gastrectomy 5.Aged between 18 and 75 years 6.Informed consent.

Exclusion criteria

Exclusion criteria: 1.Without endoscopy examination 2. Chronic atrophic gastritis, gastric ulcer,gastric polyps or other benign gastric tumor by endoscopy examination 3.Metabolic disease including hyperthyroidism,diabetes or else 4.Pregnancy or lactating women 5.Comorbidities including cardiovascular disease, abnormal renal and liver function disease, coagulation disorder or neuropsychological diseases 6.Active infectious diseases 7.Previous or combined malignancies

Design outcomes

Primary

MeasureTime frame
5-year survival rate;metabolomics;

Countries

China

Contacts

Public ContactChen Yinan

The First Affiliated Hospital of Xiamen University

chenyinan604@126.com+86 157 1158 0331

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026